The data underlying the results presented in the study are found in the supporting information of this manuscript.

Introduction {#sec004}
============

A biomarker is a surrogate indicator of biological processes occurring in an individual. Biomarkers provide information about the pathology of a disease or condition, as well as the response to a pathogen or treatment. In the context of traumatic brain injury (TBI), biomarkers have the potential to be used as diagnostic markers of injury severity, as well as markers of response to treatment (monitoring biomarkers) or even as predictors of outcomes after trauma (predictive biomarkers).

Recently, the Brain Trauma Indicator has been authorized by the FDA to evaluate concussion in adults. This indicator is obtained by measuring the levels of ubiquitin C-terminal hydro-lase--L1 (UCH-L1) and glial acidic fibrillary protein (GFAP) in blood within 12 hours after trauma \[[@pone.0210128.ref001]--[@pone.0210128.ref003]\]. Other promising biomarkers have been suggested for diagnosis, monitoring and prognosis of traumatic brain injury (TBI) such as microtubule-associated protein-2 (MAP2, neuron-specific enolase (NSE), myelin basic protein (MBP), tau, s100β and neurofilament heavy chain protein (NF-H) \[[@pone.0210128.ref004]--[@pone.0210128.ref006]\]. However, these proteins are yet to be approved for the clinical care of TBI patients. In addition, heart fatty acid binding protein (H-FABP), when combined with interleukin (IL)-10, S100β and GFAP, has been shown to be elevated in patients positive for brain damage as determined by a head CT scan \[[@pone.0210128.ref007]\].

The innate immune response is a significant contributor to inflammation after TBI that is regulated by inflammasomes. To date several inflammasomes have been shown to play a role in the inflammatory response in the nervous system. For instance, the first inflammasome to be described in the nervous system was the NLRP1 inflammasome that is activated in neurons after spinal cord injury \[[@pone.0210128.ref008]\], brain injury \[[@pone.0210128.ref009]\] and stroke \[[@pone.0210128.ref010]\]. Moreover, the NLRP2 inflammasome in astrocytes has been shown to be involved in the inflammatory response after ATP stimulation \[[@pone.0210128.ref011]\]. The most studied inflammasome is the NLRP3 inflammasome and is is present in microglia and astrocytes \[[@pone.0210128.ref012]--[@pone.0210128.ref014]\]. Additionally, the NLRC4 inflammasome is present in astrocytes \[[@pone.0210128.ref014]\], and the AIM-2 inflammasome in neurons \[[@pone.0210128.ref015]\]. Inflammasome activation involves sensing of a particular trigger by cytosolic receptors such as NOD-like receptors (NLRs) or AIM-2 like receptors (ALRs). This activation process is triggered following the formation of large multiprotein complex called the inflammasome \[[@pone.0210128.ref016]\]. These inflammasome complexes undergo oligomerization that then serves as a platform to activate inflammatory caspases. However, some differences remain in that NLRP1 and NLRC4 can activate caspase-1 without ASC oligomerization, but ASC substantially improves the production of IL-1β. Thus, it is likely that inflammasomes that do not rely on ASC for assembly are less stable and as a result the inflammatory response mounted is weaker than it would be in the presence of ASC \[[@pone.0210128.ref017], [@pone.0210128.ref018]\]. Inflammasomes process inflammatory cytokines such as interleukin(IL)-1β and IL-18 through the activation of caspase-1 \[[@pone.0210128.ref018]\]. We have previously shown that inflammasomes contribute to the pathology of TBI and that inhibition of the inflammasome results in decreased inflammation and improved histopathological outcomes after brain injury \[[@pone.0210128.ref009]\]. Moreover, inflammasome proteins are secreted after injury in extracellular vesicles isolated from serum \[[@pone.0210128.ref019]\] and CSF \[[@pone.0210128.ref020]\] that add to the systemic inflammatory response after trauma \[[@pone.0210128.ref018], [@pone.0210128.ref021]\].

In this study, we provide receiver operator characteristic (ROC) curves with associated confidence intervals (CI) following analyses of serum and CSF samples from patients with TBI and from no-TBI control donors. In addition, we determine the sensitivity and specificity of inflammasome proteins to examine the potential of the inflammasome signaling proteins caspase-1, ASC, IL-1β and IL-18 as biomarkers of TBI.

Methods {#sec005}
=======

Participants {#sec006}
------------

Serum and CSF samples from patients with TBI and samples from no-TBI control donors were used in this study. Twenty-one TBI serum and 18 CSF samples were obtained after informed consent. Informed consent was obtained from a family member or proxy according to the University of Miami Miller School of Medicine IRB protocol \# 20030154. All subjects were admitted to the Neurological Intensive Care Unit and/or the Ryder Trauma Center at Jackson Memorial Hospital (**[Table 1](#pone.0210128.t001){ref-type="table"}**). Samples from normal donors (120 samples) were purchased from Bioreclamation*IVT*. The normal donor group consisted of samples obtained from 60 male and 60 female donors in the age range of 20 to 70 years old (**[Table 2](#pone.0210128.t002){ref-type="table"}**). Thirty control CSF samples were obtained from Bioreclamation*IVT*. TBI Samples were collected three times a day for the first 5 days after patients arrived to the hospital. Samples were analyzed for the 1^st^, 2^nd^ collection (Day 1) as well as 4^th^ and 6^th^ collections (Day 2). Later time points were analyzed but the data was not shown to be significant (data not shown).

10.1371/journal.pone.0210128.t001

###### Subjects with TBI.

![](pone.0210128.t001){#pone.0210128.t001g}

  Age             Gender   Race      Mechanism of Injury                                   Injury                       GCS at resus   GOSE   Outcome
  --------------- -------- --------- ----------------------------------------------------- ---------------------------- -------------- ------ -----------------
  81 (Deceased)   Female   White     Blunt injury                                          Contusion, IVH, tSAH         3              1      Deceased
  26              Male     Unknown   Gunshot wound                                         Contusion, tSAH,             3              3      Unfavorable
  29              Male     Black     s/p MCC with helmet                                   Contusion, DAI               3              6      Favorable
  69 (Deceased)   Male     Black     Blunt injury                                          SDH, tSAH                    8              1      Deceased
  23              Male     White     MVA w/blunt injury                                    SDH, t SAH                   3              2      Unfavorable
  22              Male     Black     GSW to back of head                                   LSDH, contusion              4              8      Favorable
  70              Male     White     Blunt injury/assault                                  SDH                          10             3      Unfavorable
  21 (Deceased)   Male     White     Blunt injury pedestrian struck by car w/head injury   SDH                          3              1      Deceased
  22              Male     White     Blunt injury punched to head and fell                 SDH                          4              6      Moderate
  80 (Deceased)   Male     White     Penetrating injury, GSW to posterior head             Contusion, IVH               3              1      Deceased
  71              Female   White     Blunt injury. MVC                                                                  3              1      Deceased
  51 (Deceased)   Male     Black     Blunt injury, hit by car while biking                 tSAH, contusion, IVH         3              1      Deceased
  39 (Deceased)   Male     Unknown   MVA w/ blunt injury                                   tSAH, IVH                    3              1      Deceased
  18              Female   White     Blunt injury                                          SDH, contusion               5              7      Favorable/Rehab
  23 (Deceased)   Male     White     MCA w/blunt injury                                    Contusions, DAI, tSAH        3              1      Deceased
  21              Male     Black     GSW to head w/ penetrating injury                     tSAH, Contusion              5              4      Unfavorable
  63              Male     White     Blunt injury                                          tSAH, SDH, Contusion         7              1      Deceased
  21              Male     White     MVA w/blunt injury                                    Contusion, DAI, tSAH         5              3      Unfavorable
  45              Male     White     MVC blunt injury                                      SDH, contusions, tSAH, IVH   8              2      Unfavorable
  51              Male     White     Blunt injury                                          EDH, SDH, tSAH               3              7      Favorable/Rehab
  22              Male     White     MVC w/blunt injury                                    tSAH, SDH, contusion         3              4      Unfavorable

**s/p**: status-post; **MCC**: Motor cycle crash; **MVA**: Motor Vehicle Accident; **GSW**: Gunshot wound; **MVC**: Motor Vehicle accident; **MCA**: Motor cycle accident; **IVH**: Intraventricular bleeding; **tSAH**: traumatic Subarachnoid bleeding; **DAI**: Diffuse Axonal Injury; **SDH**: Subdural hematoma; **LSDH**: Left Subdural hematoma; **GCS at resus**: Glasgow Coma Scale at resuscitation; **GOSE**: Glasgow Outcome Scale (Extended).

10.1371/journal.pone.0210128.t002

###### Summary of control and subjects with TBI.

![](pone.0210128.t002){#pone.0210128.t002g}

                         Control              TBI
  ---------------------- -------------------- --------------------
  **Sample Size**        120                  21
  **Gender**                                   
  Male                   60                   18
  Female                 60                   3
  **Age Range**          20--70 y/o           21--81 y/o
  **Race**                                     
                         White: 28            White: 13
                         Black: 65            Black: 5
                         Hispanic: 27         Unknown: 2
  **ASC Levels**                               
  Range                  105.6--458.3 pg/ml   138.5--1720 pg/ml
  Mean                   236.6 pg/ml          629 pg/ml
  **Caspase-1 Levels**                         
  Range                  0.952--2.703 pg/ml   0.918--20.55 pg/ml
  a                      1.436 pg/ml          4.540 pg/ml
  **IL-18 Levels**                             
  Range                  40.5--422.7 pg/ml    43.72--587.7 pg/ml
  Mean                   213.5 pg/ml          218.625 pg/ml
  **IL-1beta Levels**                          
  Range                  0.413--3.276 pg/ml   0.4--4.674 pg/ml
  Mean                   1.214 pg/ml          1.0618 pg/ml

**y/o**: years old.

Simple Plex Assay {#sec007}
-----------------

Analysis of inflammasome protein concentration in serum and CSF samples were performed using the Ella System (Protein System) as described in \[[@pone.0210128.ref022], [@pone.0210128.ref023]\].

Biomarker analyses {#sec008}
------------------

Data obtained by the Simple Plex assay were analyzed with Prism 7 software (GraphPad). Analyses were carried after removing outliers, and the area under the ROC curve and the 95% confidence interval (CI) were determined. The p-value of significance used was \<0.05. Sensitivity and specificity of each biomarker was obtained for a range of different cut-off points. Samples that resulted in values outside the level of detection of the assay were not included in the analyses \[[@pone.0210128.ref022], [@pone.0210128.ref023]\]. Multiple group comparisons were carried out using a Kruskal-Wallis test ANOVA followed by Dunn's multiple comparisons test. Paired comparisons were performed using a two-tailed t-test. Normality was evaluated using the D\'Agostino and Pearson normality test. Difference in sample size throughout the study is due to the removal of outliers and because the protein concentration of some samples was out of the range of detection of the assay for some of the analytes and was not evaluated. The box plot shows the 5^th^ and 95^th^ percentiles, and the line inside the box represents the median.

Results {#sec009}
=======

ASC and caspase-1 are elevated in the serum of patients after TBI {#sec010}
-----------------------------------------------------------------

We analyzed serum samples (**[S1 Table](#pone.0210128.s001){ref-type="supplementary-material"}**) from TBI patients and compared them to serum from healthy/control individuals using a Simple Plex assay (Protein Simple) for the protein expression levels of ASC (**[Fig 1A](#pone.0210128.g001){ref-type="fig"}**), caspase-1 (**[Fig 1B](#pone.0210128.g001){ref-type="fig"})**, IL-18 (**[Fig 1C](#pone.0210128.g001){ref-type="fig"})** and IL-1β (**[Fig 1D](#pone.0210128.g001){ref-type="fig"}**). Samples were collected three times a day for five days. Data shown corresponds to the 1^st^, 2^nd^ 4^th^ and 6^th^ collection. We determined that the protein levels of ASC were higher in TBI samples (1^st^ collection: 693.5+/-108.5 pg/ml, 2^nd^: 562.6+/-84.51 pg/ml, 4^th^: 601.7+/-64.4 pg/ml, 6^th^: 658.2+/-79.69 pg/ml) when compared to samples from subjects without TBI (control, 236.6+/-7.758 pg/ml) (**[Fig 1A](#pone.0210128.g001){ref-type="fig"}**). Thus, indicating that inflammasome proteins are elevated in serum after TBI.

![Inflammasome proteins are elevated in the serum of TBI patients.\
Protein levels in pg/ml of ASC (**A**), caspase-1 (B), IL-18 (C) and IL-1β (D) in serum samples from patients with TBI and healthy donors (controls). ASC: N = 120 control, 20 TBI. Caspase-1: N = 11 control, 19 TBI. IL-18: N = 120 control, 21 TBI. IL-1β: N = 25 control, 10 TBI. Box and whiskers are shown for the 5^th^ and 95^th^ percentile. \* p \< 0.05.](pone.0210128.g001){#pone.0210128.g001}

ASC and Caspase-1 are promising serum biomarkers of TBI {#sec011}
-------------------------------------------------------

To determine if these inflammasome signaling proteins are reliable biomarkers for TBI in serum, we determined the area under the curve (AUC) for caspase-1 (**[Fig 2A](#pone.0210128.g002){ref-type="fig"}**), ASC (**[Fig 2B](#pone.0210128.g002){ref-type="fig"}**), IL-1β (**[Fig 2C](#pone.0210128.g002){ref-type="fig"}**) and IL-18 (**[Fig 2D](#pone.0210128.g002){ref-type="fig"}**). AUC values were highest for caspase-1 and ASC (**[Fig 2](#pone.0210128.g002){ref-type="fig"}**) with 0.93 (4^th^ collection) and 0.90 (6^th^ collection), respectively (**[Table 3](#pone.0210128.t003){ref-type="table"}**).

![ROC curves for caspase-1 (**A**), ASC (**B**), IL-1β (**C**) and IL-18 (**D**) from serum samples of TBI patients and healthy donors.](pone.0210128.g002){#pone.0210128.g002}

10.1371/journal.pone.0210128.t003

###### ROC analysis results for inflammasome signaling proteins in serum including area, standard error (STD. ERROR), 95% confidence interval (CI) and p-value for collections 1^st^, 2^nd^, 4^th^ and 6^th^.

![](pone.0210128.t003){#pone.0210128.t003g}

  Caspase-1 Serum      AREA     STD. ERROR   95% C.I.           P VALUE
  -------------------- -------- ------------ ------------------ ----------
  1^st^ Collection     0.78     0.08772      0.6058 to 0.9497   0.01
  2^nd^ Collection     0.83     0.0479       0.8395 to 1.027    0.005
  4^th^ Collection     0.93     0.1407       0.8353 to 0.8869   0.0002
  6^th^ Collection     0.91     0.06065      0.7888 to 1.027    0.001
  **ASC Serum**                                                 
  1^st^ Collection     0.80     0.06472      0.6762 to 0.9299   \<0.0001
  2^nd^ Collection     0.84     0.05026      0.7425 to 0.9395   \<0.0001
  4^th^ Collection     0.89     0.04898      0.7931 to 0.9851   \<0.0001
  6^th^ Collection     0.90     0.0697       0.759 to 1.032     \<0.0001
  **IL-1beta Serum**                                            
  1^st^ Collection     0.7      0.0965       0.5109 to 0.8891   0.0759
  2^nd^ Collection     0.64     0.1182       0.4085 to 0.8719   0.2304
  4^th^ Collection     0.6234   0.09765      0.432 to 0.8148    0.2582
  6^th^ Collection     0.6984   0.1162       0.4707 to 0.9261   0.1448
  **IL-18 Serum**                                               
  1^st^ Collection     0.61     0.07475      0.4593 to 0.7524   0.1227
  2^nd^ Collection     0.55     0.07064      0.4082 to 0.6851   0.4966
  4^th^ Collection     0.51     0.0713       0.372 to 0.6515    0.8666
  6^th^ Collection     0.55     0.1015       0.3532 to 0.7509   0.5387

Furthermore, the cut-off point for caspase-1 was 1.943 pg/ml with 94% sensitivity and 89% specificity (**[Table 4](#pone.0210128.t004){ref-type="table"}**). For ASC, the cut-off point was 451.3 pg/ml with 85% sensitivity and 99% specificity (**[Table 4](#pone.0210128.t004){ref-type="table"}**); whereas values for caspase-1 showed 100% sensitivity and the cut-off point was 1.679 pg/ml with 77.78% specificity. For ASC, the cut-off point was 153.4 pg/ml and a 19% specificity. In the case of caspase-1, for 100% specificity, the cut-off point was 2.717 pg/ml with 78% sensitivity. For ASC with 100% specificity, the cut-off point was 462.4 pg/ml with 85% sensitivity. Thus, these findings indicate that caspase-1 and ASC are reliable serum biomarkers for TBI.

10.1371/journal.pone.0210128.t004

###### ROC analysis results for caspase-1 and ASC in serum including cut-off point in pg/ml, sensitivity and specificity, as well as positive and negative likelihood ratios (LR+/LR-).

![](pone.0210128.t004){#pone.0210128.t004g}

  Caspase-1 Serum    Cut-off point (pg/ml)   Sensitivity (%)   Specificity (%)   LR +    LR -
  ------------------ ----------------------- ----------------- ----------------- ------- ----------
  1^st^ Collection   \> 1.439                83                67                2.50    0.25
  2^nd^ Collection   \> 1.531                94                78                4.24    0.08
  4^th^ Collection   \> 1.943                94                89                8.50    *0*.*06*
  6^th^ Collection   \> 1.947                85                89                7.62    0.17
  **ASC Serum**                                                                          
  1^st^ Collection   \> 210                  85                43                1.50    0.35
  2^nd^ Collection   \> 275                  81                72                2.91    0.26
  4^th^ Collection   \> 339.4                80                88                6.57    0.23
  6^th^ Collection   \> 451.3                85                99                97.26   0.16

ASC and IL-18 are elevated in the CSF of patients after TBI {#sec012}
-----------------------------------------------------------

We then analyzed CSF samples (**[S2 Table](#pone.0210128.s002){ref-type="supplementary-material"}**) from TBI patients and compared them to CSF from no-TBI control individuals for the protein expression of ASC ([Fig 3A](#pone.0210128.g003){ref-type="fig"}) and IL-18 ([Fig 3B](#pone.0210128.g003){ref-type="fig"}). The protein levels of ASC and IL-18 were higher in TBI samples (ASC 1^st^: 473.8+/-129.4 pg/ml, 2^nd^: 132.8+/-24.45 pg/ml, 4^th^: 362.1+/-106.3 pg/ml, 6^th^: 325.4+/-124.4 pg/ml, IL-18: 1^st^: 9.164+/-2.169, 2^nd^: 4.626+/-0.7595 pg/ml, 4^th^: 4.169+/-0.7801 pg/ml) when compared to control samples (ASC: 48.52+/-2.259 pg/ml, IL-18: 2.246+/-0.1971). Moreover, the protein concentration of caspase-1 and IL-1β in the CSF was below the level of detection of the assay. Thus, we were unable to carry out any statistical analysis for these two proteins in the present study. These findings are consistent with previous reports indicating a role for the inflammasome in the pathology of TBI \[[@pone.0210128.ref020], [@pone.0210128.ref024]\].

![Inflammasome proteins are elevated in the CSF of TBI patients.\
Protein levels in pg/ml of ASC (**A**) and IL-18 (**B**) in CSF samples from patients with TBI and healthy donors (controls). ASC: N = 21 control, 15 TBI. IL-18: N = 24 control, 16 TBI. Box and whiskers are shown for the 5^th^ and 95^th^ percentile. \* p \< 0.05.](pone.0210128.g003){#pone.0210128.g003}

ASC and IL-18 are reliable CSF biomarkers of TBI {#sec013}
------------------------------------------------

Next, we determined whether ASC and IL-18 are reliable biomarkers in CSF for TBI. The area under the curve (AUC) for ASC (**[Fig 4A](#pone.0210128.g004){ref-type="fig"}**) was 1.0 for the 6^th^ collection (**[Table 5](#pone.0210128.t005){ref-type="table"}**), and for IL-18 (**[Fig 4B](#pone.0210128.g004){ref-type="fig"}**) the AUC was 0.84 for the 1^st^ collection (**[Table 5](#pone.0210128.t005){ref-type="table"}**), indicating that ASC is a more reliable biomarker than IL-18 in CSF after TBI.

![ROC curves for ASC (**A**) and IL-18 (**B**) from CSF samples of TBI patients and healthy donors.](pone.0210128.g004){#pone.0210128.g004}

10.1371/journal.pone.0210128.t005

###### ROC analysis results for ASC and IL-18 in CSF including area, standard error (STD. ERROR), 95% confidence interval (CI) and p-value for collections 1^st^, 2^nd^, 4^th^ and 6^th^.

![](pone.0210128.t005){#pone.0210128.t005g}

  ASC CSF            AREA     STD. ERROR   95% C.I.           P VALUE
  ------------------ -------- ------------ ------------------ ----------
  1^st^ Collection   0.981    0.0195       0.9427 to 1.019    \<0.0001
  2^nd^ Collection   0.8418   0.07661      0.6917 to 0.992    0.0021
  4^th^ Collection   0.898    0.07262      0.7556 to 1.04     0.0003
  6^th^ Collection   1        0            1 to 1             0.0001
  **IL-18 CSF**                                               
  1^st^ Collection   0.8404   0.0731       0.6971 to 0.9836   0.0008
  2^nd^ Collection   0.8195   0.07969      0.6634 to 0.9757   0.002
  4^th^ Collection   0.7632   0.1061       0.552 to 0.9711    0.9711
  6^th^ Collection   0.5132   0.1344       0.2498 to 0.7765   0.9154

The cut-off point for ASC was 74.33 pg/ml with 100% sensitivity and 100% specificity (**[Table 6](#pone.0210128.t006){ref-type="table"}**). For IL-18, the cut-off point was 2.722 pg/ml with 80% sensitivity and 68% specificity (**[Table 6](#pone.0210128.t006){ref-type="table"}**). In the case of IL-18, for 100% specificity, the cut-off point was 3.879 pg/ml with 60% sensitivity, and for 100% sensitivity, the cut-off point was 1.358 pg/ml with 16% specificity. Thus, these findings indicate that ASC and IL-18 are promising biomarkers in CSF for TBI.

10.1371/journal.pone.0210128.t006

###### ROC analysis results for ASC and IL-18 in CSF including cut-off point in pg/ml, sensitivity and specificity, as well as positive and negative likelihood ratios (LR+/LR-).

![](pone.0210128.t006){#pone.0210128.t006g}

  ASC CSF            Cut-off point (pg/ml)   Sensitivity (%)   Specificity (%)   LR +   LR -
  ------------------ ----------------------- ----------------- ----------------- ------ ------
  1^st^ Collection   \> 55.11                100               85.71             7      0
  2^nd^ Collection   \> 50.25                78.57             64.29             2.20   0.33
  4^th^ Collection   \> 64.58                85.71             92.86             12     0.15
  6^th^ Collection   \> 74.33                100               100                      0
  **IL-18 CSF**                                                                         
  1^st^ Collection   \> 2.722                80                68.42             2.53   0.29
  2^nd^ Collection   \> 2.221                85.71             57.89             2.04   0.25
  4^th^ Collection   \> 3.055                70                84.21             4.43   0.36
  6^th^ Collection   \> 1.707                75                36.84             1.19   0.68

ASC is elevated in the serum of patients with unfavorable outcomes after TBI {#sec014}
----------------------------------------------------------------------------

We then separated the TBI patients according to their clinical outcomes (**[S3 Table](#pone.0210128.s003){ref-type="supplementary-material"}**); either favorable or unfavorable outcomes based on the Glasgow Outcome Scale-Extended (GOSE) in which patients with a score of 6 to 8 were considered to have favorable outcomes and those with a score of 1 to 4 were considered to have unfavorable outcomes (**[Table 1](#pone.0210128.t001){ref-type="table"}**). We found that the protein level of ASC was higher in the serum of TBI patients with unfavorable outcomes (2^nd^: 652.9+/-100.9pg/ml, 4^th^: 719.2+/-68.14 pg/ml) when compared to the samples obtained from patients with favorable outcomes (2^nd^: 273.7+/-19.41 pg/ml, 4^th^: 327.6+/-53.84 pg/ml) (**[Fig 5B](#pone.0210128.g005){ref-type="fig"}**), whereas the caspase-1 (**[Fig 5A](#pone.0210128.g005){ref-type="fig"}**) and IL-18 (**[Fig 5C](#pone.0210128.g005){ref-type="fig"}**) levels were not statistically different between the two groups.

![Inflammasome proteins as predictive biomarkers of TBI.\
Protein levels in pg/ml of caspase-1 (**A**), ASC (**B**), and IL-18 (**C**) in serum samples from patients with TBI. Groups were divided into favorable and unfavorable outcomes based on the GOSE. p-value of significance is shown above each box plot. Box and whiskers are shown for the 5^th^ and 95^th^ percentile. Caspase-1: N = 4 favorable and 16 unfavorable ASC: N = 5 favorable and 16 unfavorable; and IL-18: N = 5 favorable and 16 unfavorable.](pone.0210128.g005){#pone.0210128.g005}

ASC is a promising predictive biomarker of TBI in serum {#sec015}
-------------------------------------------------------

To determine if ASC in serum can be used as predictive biomarkers of TBI, we determined the AUC for ASC at the 2^nd^ (**[Fig 6A](#pone.0210128.g006){ref-type="fig"}**) and 4^th^ collection (**[Fig 6B](#pone.0210128.g006){ref-type="fig"}**). The AUC for ASC was 0.9167 in the 4^th^ collection with a CI between 0.7914 and 1.042 (**[Table 7](#pone.0210128.t007){ref-type="table"}**). Furthermore, the cut-off point was 547.6 pg/ml with 86% sensitivity and 100% specificity (**[Table 8](#pone.0210128.t008){ref-type="table"})**. Thus, these findings indicate that ASC is an excellent predictive biomarker of TBI.

![ROC curves for ASC outcomes (Favorable vs. Unfavorable) for the 2^nd^ and 4^th^ collection.](pone.0210128.g006){#pone.0210128.g006}

10.1371/journal.pone.0210128.t007

###### ROC analysis results for ASC in serum for Favorable vs Unfavorable outcomes, including area, standard error (STD. ERROR), 95% confidence interval (CI) and p-value for collections 1^st^, 2^nd^ and 4^th^.

![](pone.0210128.t007){#pone.0210128.t007g}

  ASC Serum (GOSE)   AREA     STD. ERROR   95% C.I.          P VALUE
  ------------------ -------- ------------ ----------------- ---------
  1^st^ Collection   0.7625   0.1133       0.544 to 0.9846   0.0829
  2^nd^ Collection   0.85     0.08355      0.6862 to 1.014   0.0208
  4^th^ Collection   0.9167   0.06391      0.7914 to 1.042   0.0039

10.1371/journal.pone.0210128.t008

###### ROC analysis results for ASC in serum for Favorable vs Unfavorable outcomes, including cut-off point in pg/ml, sensitivity and specificity, as well as positive and negative likelihood ratios (LR+/LR-) for collections 1^st^, 2^nd^ and 4^th^.

![](pone.0210128.t008){#pone.0210128.t008g}

  ASC Serum (GOSE)   CUT-OFF POINT (pg/ml)   SENSITIVITY (%)   SPECIFICITY (%)   LR +   LR -
  ------------------ ----------------------- ----------------- ----------------- ------ ------
  1^st^ Collection   \> 353.7                75                80                3.75   0.31
  2^nd^ Collection   \> 311.2                81.25             80                4.06   0.23
  4^th^ Collection   \> 547.6                85.71             100                      0.14

Discussion {#sec016}
==========

TBI affects approximately 10 million people worldwide and has become a major cause of death and disability \[[@pone.0210128.ref025]\]. TBI severity is categorized as mild, moderate or severe. Signs and symptoms of TBI may include loss of consciousness, amnesia, nausea, dizziness, headaches, cognitive decline, structural brain damage and presence of other neurological symptoms \[[@pone.0210128.ref026]\]. The level of consciousness after TBI is often used to determine the severity of trauma in the Glasgow Coma Scale (GCS) score. This score is combined with brain radiographic imaging, other neurological findings and fluid biomarkers to assess the clinical status of the patient\[[@pone.0210128.ref027]\]. Fluid biomarkers can be obtained from CSF, serum or plasma. Potential biomarkers for the care of patients with TBI include total tau (T-Tau), amyloid-β (Aβ), UCH-L1, NSE, spectrin-α chain, S100B and GFAP \[[@pone.0210128.ref026]\]. Although there appears to be a variety of candidate proteins that may be potentially used as biomarkers, many studies have only looked at protein levels across patient cohorts including controls. Many of the studies aiming at identify biomarkers of TBI have failed to use the adequate statistical analyses that are needed to determine the suitability of a protein as a biomarker. These analyses include determination of the AUC, sensitivity, specificity and likelihood ratio as well as positive and negative predictive values \[[@pone.0210128.ref023]\]. Currently, there is only one approved FDA test for blood-based biomarkers in the United States, involving GFAP and UCH-L1, \[[@pone.0210128.ref028]\] which was approved this year.

In the present study, we show that ASC and IL-18 are reliable biomarkers for TBI in CSF with AUC values of 1.0 and 0.84, respectively. Most importantly, since obtaining CSF is a very invasive procedure, our finding that inflammasome proteins are elevated in serum, opens the possibility of using a less invasive test such as a blood test for biomarker analysis. In serum, we found that the AUC values for ASC was 0.90 and for caspase-1, 0.93. Thus, of the inflammasome proteins that we tested in this study, caspase-1 and ASC are the best candidate biomarkers in serum for the care of patients with brain injury. Thus, the development of a clinically validated brain biomarker test involving inflammasome proteins has the potential to alter diagnostic approaches and development of clinical care procedures of TBI subjects.

The importance of inflammasome regulation in TBI secondary injury processes has been recently reported. The NLRP1 inflammasome plays a significant role in the inflammatory response after TBI\[[@pone.0210128.ref009]\], and inhibition of NLRP1 signaling by antibody neurtralization results in decreased inflammation and improved histopathology after brain injury \[[@pone.0210128.ref009]\]. Additionally, the NLRP3 inflammasome is activated after brain injury \[[@pone.0210128.ref029], [@pone.0210128.ref030]\], and inhibition of the NLRP3 inflammasome results in decreased inflammation and improved neurological function in a mouse model of brain injury \[[@pone.0210128.ref031], [@pone.0210128.ref032]\]. The AIM2 inflammasome has been associated with the inflammasome-mediated cell death mechanism of pyroptosis, thus affecting blood brain barrier permeability after trauma \[[@pone.0210128.ref015], [@pone.0210128.ref033]\]. Inflammasome proteins are elevated in the CSF of patients with TBI, and high levels of these proteins correlate with poor outcomes in the chronic stages after injury \[[@pone.0210128.ref024]\]. Lastly, hyperbaric oxygen therapy, \[[@pone.0210128.ref034]\] hypothermia, \[[@pone.0210128.ref035]\] omega-3 fatty acids, \[[@pone.0210128.ref036]\] resveratrol\[[@pone.0210128.ref037]\] and propofol \[[@pone.0210128.ref038]\] provide beneficial effects after TBI by lowering inflammasome activation. Thus, innate immune inflammatory processes regulated by inflammasomes play an integral role in pathological processes following TBI.

Standards for Reporting Diagnostic accuracy studies (STARD) guidelines were used in this study. However, our study has several limitations. For example, the sample collection time points from patients after trauma was not uniform. As a result, the second collection of samples from patients varied after trauma. In addition, we were unable to collect CSF from all patients, and as a result the number of CSF samples are lower when compared to the number of serum samples. In addition, most samples collected in this study were obtained from subjects with severe TBI. Thus, future studies are needed to evaluate the prognostic potential of these biomarker in patients with mild TBI. Moreover, patients enrolled in this study suffered from isolated head trauma (i.e. gunshot wound) or had polytrauma (i.e. motorvehicle accident). As a result, it is likely that the effects of trauma on serum levels of inflammasome proteins are not entirely related to brain injury but to tissue damage originating in other organs such as lung \[[@pone.0210128.ref019]\], spleen or liver. Lastly, our study involved Whites and Blacks but did not contain Hispanics or other races in the TBI cohort.

We have recently shown that inflammasome proteins may be used as biomarkers of multiple sclerosis, stroke and depression \[[@pone.0210128.ref023], [@pone.0210128.ref039], [@pone.0210128.ref040]\]. However, patients in each disease category present different levels of inflammasome proteins and these levels may vary depending on disease severity. Thus, it is likely that these proteins may be used to monitor disease inflammatory progression or severity. The specificity of inflammasome proteins as biomarkers may be altered by changing the cut-off point to reflect a different sensitivity since sensitivity and specificity are inversely correlated such that as specificity increases, sensitivity decreases. In this study, we chose to set cut-off points that provided high sensitivity and the highest possible specificity for all analytes. Therefore, for clinical purposes the sensitivity should be set at the highest level and the specificity may be increased by the addition of other clinical findings such as imaging biomarkers, symptoms or other fluid-based biomarkers.

In conclusion, in this study we show that the inflammasome protein ASC may be use as a biomarker of TBI in serum and CSF, whereas caspase-1 may be used as a serum biomarker and IL-18 as a biomarker in CSF. In future studies, we will analyze these biomarkers in larger cohorts of patients with more stratified and specific types of brain injury. Importantly, the identification of these proteins as biomarkers is also indicative of their potential as therapeutic targets for the treatment of inflammation after trauma.
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